Ranitidine
/api/v1/drug/ranitidineMechanism of action
Sourced from openFDAMechanism-of-action class: Histamine H2 Receptor Antagonists.
Indications
Sourced from openFDA- Use(s) relieves heartburn associated with acid indigestion and sour stomach prevents heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certain foods and beverages
Dosage & administration
Sourced from openFDADirections adults and children 12 years and over: to relieve symptoms, swallow 1 tablet with a glass of water to prevent symptoms, swallow 1 tablet with a glass of water 30 to 60 minutes before eating food or drinking beverages that cause heartburn can be used up to twice daily (do not take more than 2 tablets in 24 hours) children under 12 years: ask a doctor
Warnings & precautions
Sourced from openFDAAllergy alert: Do not use if you are allergic to ranitidine or other acid reducers Do not use if you have trouble or pain swallowing food, vomiting with blood, or bloody or black stools.These may be signs of a serious condition. See your doctor. with other acid reducers Ask a doctor before use if you have had heartburn over 3 months. This may be a sign of a more serious condition. heartburn with lightheadedness, sweating or dizziness chest pain or shoulder pain with shortness of breath; sweating; pain spreading to arms, neck or shoulders; or lightheadedness frequent chest pain frequent wheezing, particularly with heartburn unexplained weight loss nausea or vomiting stomach pain kidney disease Ask a doctor or pharmacist before use if you are • taking a prescription drug. Acid reducers may interact with certain prescription drugs. Stop use and ask doctor if your heartburn continues or worsens you need to take this product for more than 14 days If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222).
Approval history
Sourced from openFDA- Mar 28, 2000ANDAANDA075294Dr Reddys Labs Ltd
- Nov 29, 2000ANDAANDA075742Dr Reddys Labs Ltd
- Oct 13, 2006ANDAANDA077824Amneal Pharms Ny
- Aug 31, 2007ANDAANDA078192Dr Reddys Labs Ltd
- Sep 21, 2007ANDAANDA077405Pharm Assoc
- Feb 29, 2012ANDAANDA201745Strides Pharma
- Aug 20, 2018ANDAANDA210243Granules
- Sep 27, 2018ANDAANDA209859Ajanta Pharma Ltd
FAERS reports
- 1Breast Cancer29,41313%
- 2Prostate Cancer26,44611%
- 3Colorectal Cancer20,7209.0%
- 4Bladder Cancer19,2078.3%
- 5Renal Cancer19,0358.3%
- 6Oesophageal Carcinoma11,0664.8%
- 7Incorrect Dose Administered9,7424.2%
- 8Hepatic Cancer8,8343.8%
- 9Gastric Cancer8,7423.8%
- 10Pancreatic Carcinoma8,0373.5%
- 11Lung Neoplasm Malignant7,9523.4%
- 12Nausea5,4362.4%
- 13Fatigue5,2432.3%
- 14Drug Ineffective5,0732.2%
- 15Chronic Kidney Disease4,9782.2%
Literature
Recent PubMed references pinned to Ranitidine as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.
- Covalently bound Eosin Y on chitosan as a removable photosensitizer for ranitidine degradation.Chemosphere · 2026 · Sacchetto JL, Barrera Llorente AM, Kuhn Beldomenico M, et al.PMID 41990718DOI 10.1016/j.chemosphere.2026.144931
- Signal-Level Determinants of Cognitive Decline With PPIs versus H(2)RAs: Transportome (CBLIF/TCN2) and CHRNA7 Nodes.Molecular nutrition & food research · 2026 · Saihati HAA, Ahmed BY, Mosaad RM, et al.PMID 41663888DOI 10.1002/mnfr.70382
- Ranitidine protects Müller cells against ferroptosis in diabetic retinopathy by regulating the AKT1/GSK3β pathway.Indian journal of ophthalmology · 2026 · He W, Qi J, Liu Z, et al.PMID 41581041DOI 10.4103/IJO.IJO_1522_25
- Enhanced adsorption of ranitidine onto activated carbon‑modified zeolite composite and investigation of the removal mechanism.Scientific reports · 2025 · Shirvani F, Hashemi M, Dolatabadi M, et al.PMID 41398206DOI 10.1038/s41598-025-32778-1
- Crystal defects cause nitrosamine formation in ranitidine under accelerated storage conditions.Journal of pharmaceutical sciences · 2025 · Xu J, Huls NJ, Jannasch AS, et al.PMID 40825482DOI 10.1016/j.xphs.2025.103960
- Mitigation of N-Nitrosamine formation in ranitidine hydrochloride by spray drying co-precipitation with mannitol, dextrin, and antioxidant.Journal of pharmaceutical sciences · 2025 · Pu S, Hadinoto KPMID 40543883DOI 10.1016/j.xphs.2025.103864
- Premedication in pediatric Meckel scintigraphy: pantoprazole versus ranitidine for optimizing scan quality.Pediatric radiology · 2025 · Önner H, Calderon Tobar MN, Sarıkaya M, et al.PMID 40515817DOI 10.1007/s00247-025-06284-5
- Doping Control of Ranitidine in Horses.Drug testing and analysis · 2025 · Ho HSM, Mizzi JX, Ho ENM, et al.PMID 40394757DOI 10.1002/dta.3909
Clinical trials
The 10 most recently updated of 110 ClinicalTrials.gov registrations naming Ranitidine as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.
- A Prospective Evaluation of Non-Operative Treatments for Gastrocutaneous Fistulae in ChildrenCompleted · Phase 4 · Interventional · 100 enrolled · University of British ColumbiaNCT03920306updated 2026-05-01
- Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal CancerTerminated · Phase 2 · Interventional · 15 enrolled · Centre Oscar LambretNCT03301454updated 2026-03-18
- Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological MalignanciesCompleted · Phase 1 · Interventional · 13 enrolled · City of Hope Medical CenterNCT04681105updated 2026-01-28
- Effect of Dexmedetomidine on the Quality of Recovery in Parturients Undergoing Elective Caesarean SectionsCompleted · Phase 4 · Interventional · 141 enrolled · Cairo UniversityNCT05991466updated 2025-12-05
- A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMTTerminated · Phase 3 · Interventional · 16 enrolled · Genzyme, a Sanofi CompanyNCT03368664updated 2025-11-26
- : Vascular Function in Health and DiseaseRecruiting · Phase 1 · Interventional · 420 enrolled · Russell RichardsonNCT02966665updated 2025-09-26
- Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney TransplantationTerminated · Phase 1 · Phase 2 · Interventional · 23 enrolled · SanofiNCT04294459updated 2025-09-17
- Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving PaclitaxelCompleted · Phase 2 · Phase 3 · Interventional · 130 enrolled · Ohio State University Comprehensive Cancer CenterNCT04862585updated 2025-08-20
- Effect of H2 Receptor Antagonist and Proton Pump Inhibitor on the Positivity Rates and Clinical Outcomes of COVID-19Completed · Observational · 400,000 enrolled · Seoul National University HospitalNCT04834752updated 2024-11-29
- Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy ParticipantsCompleted · Phase 1 · Interventional · 20 enrolled · Eli Lilly and CompanyNCT05338502updated 2024-10-30
Frequently asked questions
- How does Ranitidine work?
- Mechanism-of-action class: Histamine H2 Receptor Antagonists.
- What is Ranitidine used for?
- According to FDA labeling, Ranitidine carries indications including: Use(s) relieves heartburn associated with acid indigestion and sour stomach prevents heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certain foods and beverages. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.
- What class of drug is Ranitidine?
- Ranitidine is classified as H2-receptor antagonists, Histamine-2 Receptor Antagonist, Histamine H2 Receptor Antagonists, Decreased Histamine Activity, Inhibition Gastric Acid Secretion.
- What are the brand names for Ranitidine?
- Ranitidine is marketed under brand names including Zantac.
ranitidine is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.